The National Institute for Health and Clinical Excellence recently updated its guideline on treating and managing depression in adults. The first part of this two part unit covered the identification, assessment and initial management of persistent subthreshold depressive symptoms and mild to moderate depression. This second part looks at the core treatments for moderate to severe depression, as well as mild to moderate depression and persistent subthreshold symptoms that have not responded to low intensity interventions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Anemia in pregnancy: a systematic review and meta-analysis of prevalence, determinants, and health impacts in Egypt.
BMC Pregnancy Childbirth
January 2025
Department of Obstetrics and Gynecology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Background: The WHO considers anemia in pregnancy a severe public health issue when prevalence surpasses 40%. In response, we conducted a systematic review and meta-analysis to examine anemia among pregnant women in Egypt, focusing on its prevalence, determinants, and associated complications.
Methods: We conducted a systematic literature search for studies published between January 1, 2010, and August 18, 2024, to identify studies from Egypt reporting on anemia in pregnant women, including its prevalence, associated determinants, and complications.
Role of Endoluminal Functional Lumen Imaging Probe in Bariatric Surgery and Bariatric Endoscopy.
Obes Surg
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, School of Medicine, Washington University, St. Louis, MO, 63130, USA.
Obesity is associated with significant morbidity, with an estimated prevalence of 42.4% in the USA. Treatment of severe obesity often involves Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy.
View Article and Find Full Text PDFA multi-site feasibility study of a stepped-care telehealth intervention for depression and anxiety in post-treatment cancer survivors at community cancer clinics (WF-30917CD).
J Cancer Surviv
January 2025
Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Purpose: This feasibility study estimated accrual, retention, adherence, and summarized preliminary efficacy data from a stepped-care telehealth intervention for cancer survivors with moderate or severe levels of anxiety and/or depressive symptoms.
Methods: Participants were randomized to intervention or enhanced usual care (stratified by symptom severity). In the intervention group, those with moderate symptoms received a cognitive-behavioral therapy (CBT) workbook/6 bi-weekly check-in calls (low intensity) and severe symptoms received the workbook/12 weekly therapy sessions (high intensity).
Predictors of 7-day mortality in critically ill patients with hyperglycemic crisis : A single center retrospective analysis.
Wien Klin Wochenschr
January 2025
Department of Medicine III and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Klinik Hietzing, Vienna, Austria.
Aim/hypothesis: The main aim of the study was to identify point of care available laboratory and clinical predictors of 7‑day mortality in critically ill patients with a hyperglycemic crisis.
Methods: A retrospective study of 990 patients with the first hospitalization due to hyperglycemia was performed. Patients were classified as having diabetic ketoacidosis (DKA) or being in a hyperosmolar hyperglycemic state (HHS) according to the recommendations of the American Diabetes Association (ADA).
Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis.
Bone Marrow Transplant
January 2025
Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Belumosudil is a first in class ROCK2-inhibitor approved by the FDA for the 3rd line treatment of chronic graft-versus-host disease (cGvHD). In this retrospective real-world analysis, we report safety and efficacy data of belumosudil treatment from 5 German/Swiss transplant centers. A total of 33 adult patients (median age 59 years) with moderate (n = 2) or severe (n = 31) cGvHD were treated on individual request due to lack of EMA approval.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!